The UK’s bioindustry finds itself at a pivotal moment. The Autumn Budget has landed with a mixture of welcome boosts and fresh anxieties for life science and biotech companies — particularly those scaling-up from promising startups to globally competitive innovators.
For years, the UK BioIndustry Association (BIA) has been pressing the government to modernise the tax environment for high-growth science companies.
Outdated limits on venture investment incentives and employee share option schemes, the BIA argued, were creating unnecessary friction for firms trying to scale.
These companies, often capital-intensive and talent-hungry, rely on competitive investment structures to attract both funding and specialist skills.
This time, the message has been heard loud and clear. Jane Wall, Managing Director of the BIA, welcomed the Chancellor’s decision to extend these incentives — something the association and its members have long campaigned for.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.